<DOC>
	<DOCNO>NCT00025402</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , hydroxyurea , cytarabine , idarubicin , etoposide donor bone marrow transplant stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . Interferon alfa may interfere growth cancer cell slow growth cancer . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . It yet know whether chemotherapy effective without interferon alfa and/or bone marrow stem cell transplant treat patient chronic myelogenous leukemia . PURPOSE : This randomized phase III trial study chemotherapy biological therapy see well work compare chemotherapy , biological therapy , donor bone marrow transplant autologous stem cell transplant treat patient chronic phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Chemotherapy Biological Therapy With Without Bone Marrow Peripheral Stem Cell Transplant Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival patient chronic myelogenous leukemia early chronic phase treat allogeneic bone marrow transplantation vs drug treatment without autologous peripheral blood stem cell transplantation . - Compare survival patient late-phase disease treat high-dose cytarabine v low-dose cytarabine follow autografting interferon alfa maintenance . - Compare survival patient respond cytogenetically treatment continue interferon alfa v hydroxyurea . - Determine frequency , time-point , duration hematological cytogenetic remission Philadelphia chromosome-negative and/or BCR-ABL-positive cell various treatment . - Correlate quality hematological cytogenetic remission survival time patient treat regimen . - Compare course terminal phase patient treat regimen . - Compare toxic effect regimens patient . - Determine effect prognostic criterion normal subnormal WBC chronic phase duration survival time patient treat regimen . - Compare effect early v late high-dose therapy plus autografting feasibility , toxicity , survival time patient . OUTLINE : This randomize , multicenter study . Patients stratify accord eligibility transplantation ( yes v ) . All patient undergo cytoreduction comprise hydroxyurea ( HU ) IV daily . Patients ineligible refuse transplantation randomize 1 2 treatment arm . - Arm I : Patients receive interferon alfa ( IFN ) subcutaneously ( SC ) daily . After 2 week IFN therapy , patient also receive low-dose cytarabine ( ARA-C ) SC daily 10-15 day month . Patients achieve cytogenetic remission within 12 month continue receive HU . - Arm II : Patients receive IFN SC daily . After 2 week IFN therapy , patient also receive low-dose ARA-C SC daily 10-15 day month . Patients achieve cytogenetic remission within 12 month continue receive IFN therapy SC daily . Patients eligible transplantation relate donor undergo allogeneic bone marrow transplantation . Patients may receive HU IFN prior transplantation . Patients may also receive oral high-dose busulfan daily 4 day without cyclophosphamide cyclophosphamide total body irradiation . Patients eligible transplantation relate donor undergo peripheral blood stem cell ( PBSC ) harvest randomize 1 2 treatment arm . - Arm III : Patients receive IFN low-dose ARA-C arm I . Patients accelerate treatment may undergo autologous PBSC transplantation . - Arm IV : Patients receive idarubicin IV , ARA-C IV 2 hour , etoposide IV day 1-3 . Patients undergo leukapheresis . Beginning day 8 , patient receive filgrastim ( G-CSF ) SC daily end leukapheresis . Patients receive oral high-dose busulfan daily 4 consecutive day . The following day , patient undergo reinfusion autologous PBSC . After blood count recovery , patient receive maintenance IFN 3 time weekly 8 week daily . Patients follow every 3 month 3 year every 6 month thereafter . PROJECTED ACCRUAL : A total 1,000 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myelogenous leukemia chronic phase Previously untreated Patients negative Philadelphia chromosome BCRABL translocation must fulfill least 1 follow criterion : Impaired health status reduce exercise tolerance Spleenrelated symptoms case splenomegaly Weight loss great 10 % 6 month Fever great 38.5 degree C 5 consecutive day Clinically relevant bone pain Leukocytosis great 5,000/mm^3 Thrombocytosis great 100,000/mm^3 PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Other : No concurrent malignancy likely require treatment study likely reduce life expectancy No severe concurrent disease cause would preclude study Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interferon Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
</DOC>